← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Sidney Kimmel Cancer Center
San Diego, CA
$95,905,360
Total funding
87
Grants
Funding over time
peak $15.2M · FY2005–09$20M$15M$10M$5M$0
'05
'06
'07
'08
'09
Funding mix
By agency
NIH$93,786,295 · 83
DOD$2,119,065 · 4
By mechanism
R01$63,981,464 · 44
P01$9,089,553 · 7
R33$5,952,839 · 4
R21$5,047,329 · 14
U01$4,936,138 · 1
R24$3,264,459 · 2
Investigators at Sidney Kimmel Cancer Center
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
Largest grants
Targeting Vessels in Tumors$3,174,461
P01 · FY2005 · CA
Targeting Vessels in Tumors$2,637,795
P01 · FY2008 · CA
Targeting Vessels in Tumors$2,615,782
P01 · FY2007 · CA
Targeting Vessels in Tumors$2,612,712
P01 · FY2006 · CA
CHARACTERIZATION OF EARLY STAGE PROSTATE CANCER$1,264,810
U01 · FY2003 · CA
CHARACTERIZATION OF EARLY STAGE PROSTATE CANCER$1,235,070
U01 · FY2002 · CA
CHARACTERIZATION OF EARLY STAGE PROSTATE CANCER$1,194,334
U01 · FY2001 · CA
Technology to Unmask Accessible Tumor Vascular Targets$1,128,364
R33 · FY2002 · CA
CHARACTERIZATION OF EARLY STAGE PROSTATE CANCER$1,089,335
U01 · FY2000 · CA
Mapping Vascular Proteome for Organ Targeting in Vivo$796,492
R01 · FY2005 · HL
Technology to Unmask Accessible Tumor Vascular Targets$791,326
R33 · FY2003 · CA
Technology to Unmask Accessible Tumor Vascular Targets$789,795
R33 · FY2004 · CA
Mapping Vascular Proteome for Organ Targeting in Vivo$780,972
R01 · FY2006 · HL
Nanotechnology Platform for Targeting Solid Tumors$777,850
R01 · FY2007 · CA
Nanotechnology Platform for Targeting Solid Tumors$763,442
R01 · FY2008 · CA
Mapping Vascular Proteome for Organ Targeting in Vivo$755,456
R01 · FY2007 · HL
Mapping Vascular Proteome for Organ Targeting in Vivo$742,727
R01 · FY2008 · HL
OVARIAN TUMOR-STROMA INTERACTIONS IN AN IN VIVO ORTHOTOPIC MODEL$731,250
· FY2009 · Department of the Army
CELL-MEDIATED DELIVERY OF THERAPEUTIC ADENOVIRAL VECTORS TO METASTIC PROSTATE CANCER$723,750
· FY2008 · Department of the Army
Technology/Map Endothelial Targets/Human Renal Tumors$714,748
R33 · FY2006 · CA